Wearable wrist-watch type cuff oscillometric blood pressure monitors: consensus statement by the European Society of Hypertension Working Group on blood pressure monitoring.
Aug 2026· Journal of Hypertension· Vol 44 10, pp.
1721-1731
· 0 citations· 43 references
Medicine
TL;DR
More research is needed to establish the accuracy and clinical utility of these novel devices and their role in improving the diagnosis and management of hypertension.
Abstract
Wearable wristwatch-type cuff oscillometric blood pressure (BP) monitors represent a new category of BP devices and are the first wearable monitors to use established cuff-oscillometric BP measurement technology. This consensus statement by the European Society of Hypertension Working Group on BP Monitoring reviews the published evidence on their design, accuracy, validation, clinical application, and remaining research questions. Of 281 articles identified through a systematic PubMed search, 26 were relevant. Several devices are currently available; however, only two have published validation studies performed according to established standards (Omron HeartGuide and Huawei Watch D/D2). Static validation studies generally showed acceptable accuracy, whereas data on 24-h ambulatory use, in special populations, and clinical applications remain limited. Potential advantages include self-initiated measurement at home, at work, and in other settings and conditions; more convenient and repeatable 24-h ambulatory monitoring; more convenient and accurate assessment of asleep BP; capture of stress-related and other BP-related episodes. However, proper wrist position, user adherence, ambulatory performance, and clinical applications require further investigation. More research is needed to establish the accuracy and clinical utility of these novel devices and their role in improving the diagnosis and management of hypertension.
The 2015–2025 ecosystem shows rapid progress and a transition toward cuffless-specific validation, however, clinical utility depends on intended use, population, calibration/recalibration, and setting, and performance should not be extrapolated across technologies, populations, or contexts.
J. C. Bustamante-Rodríguez, Jhosmer Ballena-Caicedo, Julio César Bautista-Zuta et al.· Frontiers in Digital Health· 0 citations
This represents the first evaluation of a Device Type 3 cuffless blood pressure algorithm (automated, wearable, demographic-calibrated, not at heart level) meeting ESH awake/asleep test criteria, suggesting Alysis-001's potential as a clinically viable alternative for ambulatory blood pressure monitoring in hypertensiv...
Wearable and connected devices should be treated as components of an organized self-management system rather than stand-alone therapies, and future implementation should prioritize validated measurement, low-burden design, human support, interoperability, and equity-sensitive evaluation over device novelty.
Radosław Sciepuro, Marta Czarnowska, Nina Czarnowska· International Journal of Inn...· 0 citations
Abstract Background Commercially available wearable devices, capable of measuring cardiac rhythm, are gaining popularity for convenient heart health monitoring. Accurate measurement of key intervals, specifically RR intervals for rhythm and QT and corrected QT (QTc) intervals for arrhythmia risk, is crucial for assessi...
Nicholas Noggle, David Wing, J. Godino et al.· JMIR Formative Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.